Disc Medicine reports early Phase 2 data for DISC-3405 in polycythemia vera
The company said its anti-TMPRSS6 antibody cut phlebotomy events and kept hematocrit under control in an initial look at the RESTORE-PV trial.
SEC filing
Latest
2 stories
Thursday, September 10
Thursday, July 30
Disc Medicine reports Q2 2026 results, aligns with FDA on bitopertin path in EPP
Disc Medicine completed a Type A meeting with the FDA and said its ongoing Phase 3 APOLLO study could support a CRL response for bitopertin in EPP, with topline data expected in the fourth quarter of 2026.
SEC filing